Ouch: Eliem’s pain drug fails sec­ond PhII tri­al, gets scrapped

In April, Eliem Ther­a­peu­tics’ lead can­di­date, ETX-810, failed a Phase II study for di­a­bet­ic nerve pain, buck­ling the greater Seat­tle-based biotech’s stock by over half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER